Navigation Links
SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
Date:5/6/2010

BOTHELL, Wash., May 6 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE AMEX: DDD) today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation, (RedHill), granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's proprietary extended delivery technology (CDT).  Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and radiation related nausea and vomiting.  

Under the terms of the Licensing Agreement, RedHill has agreed to make up front and additional payments to SCOLR up to $600,000 based on achievement of certain regulatory milestones and the first commercial sale of the product and thereafter make payments to the Company up to a maximum of $30 million based on the aggregate net sales by RedHill of the licensed product over a ten year period.

Stephen J. Turner, SCOLR Pharma's President and CEO, said, "We believe RedHill is a strong partner to collaborate with for the further development of our CDT-based ondansetron tablet formulations. As SCOLR continues to progress its pipeline of products, we will look for key strategic alliances, such as this licensing agreement with RedHill, to maximize the value of our pharmaceutical and nutritional product portfolio."

Dror Ben-Asher, RedHill's CEO, said, "CDT-based ondansetron is the latest addition to RedHill's fast-growing pipeline of late clinical-stage drugs. We are excited about our partnership with SCOLR and intend to vigorously execute up
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
4. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
5. SCOLR Pharma, Inc. Licenses Dietary Supplements
6. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
7. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
8. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
9. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
10. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
11. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases, ... first quarter ended March 31, 2015 and provided a ... equity offering in February, which raised net proceeds ... strong financial position to advance our lead pipeline ...
(Date:5/4/2015)... 4, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... provided a regulatory update on Zalviso and reported ... 31, 2015. Zalviso Regulatory UpdateOn April ... Division of Anesthesia, Analgesia, and Addiction Products (DAAAP ...
(Date:5/4/2015)... 2015 Transportation Insight, a leading global ... client, DSI Systems Inc., are featured in the ... in the cover story emphasizing technology as the ... editorial illustrates how Transportation Insight implemented its ... growth and success of DSI,s complex supply chain. ...
Breaking Medicine Technology:Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 2AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 3AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 4AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 5AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 6AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 7AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 8Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 2Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 3
... is pleased to announce the addition of Suzie Williams , CP as ... Regional Clinical Manager.   , , ... http://www.newscom.com/cgi-bin/prnh/20100427/DA94114 ) , , , ... Suzie will be joining us as we were not only impressed by her ...
... & Reed Global Executive Search, a growing recruiting firm with offices worldwide, ... of Managing Director, Biopharmaceutical Life Sciences, effective April 15, 2010 . ... "Dave has outstanding ... recognize how important it is for our clients to work with a ...
Cached Medicine Technology:Suzie Williams, CP Joins Orthocare Innovations as Clinical Services Manager 2Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences 2
(Date:5/4/2015)... City, MO (PRWEB) May 04, 2015 ... vice president and chief physician executive, and William C. ... have received and accepted personal invitations from the Secretary ... National Security Forum (NSF) at the Air War College, ... is to expose influential citizens to senior U.S. and ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The ... Group today launched a new initiative at UC ... next generation of physicians committed to advancing Latino ... Ser Medicos, or Preparing Students to Be Physicians, ... that will provide scholarships, mentorship and internship opportunities, ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Takeda Pharmaceuticals ... billion to settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ... increases the risk that a patient will develop bladder ... 28th, if 95% of those eligible for the Actos ... 9,000 bladder cancer cases currently pending in courts around ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 McNeil ... programs, announces the expansion of coverage for its ... leading provider of industry-tailored insurance and proactive risk management ... Company, we are dedicated to providing our customers with ... their many evolving needs. We are excited to launch ...
(Date:5/4/2015)... 04, 2015 Johnson & Wales University (JWU) ... and science academic center on Wednesday, April 22. , Johnson ... land made available by the re-alignment of Interstate-195. JWU’s new ... Friendship and Chestnut streets in Providence, is scheduled to be ... parcel of land the university purchased in 2012. , “It ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3
... Ph.D. shares pioneering research with counselors June 6; ... Thanks to a Ph.D. with the,last name ... counseling,sessions including a horse can be more beneficial ... ground-breaking research with other,mental health professionals during her ...
... for the skull projected to climb at double-digit rates, ... according to Millennium Research Group, ... (MRG) US Markets for Craniomaxillofacial (CMF) Devices 2008 report,the plate ... million,in 2007 to nearly $300 million in 2012, driven in ...
... 22 Menstrual migraine, a condition,that affects ... a new supplement to OBG,Management. "Integrating menstrual ... between hormone fluctuation and,migraine, as well as ... Biologic and genetic factors in the pathogenesis ...
... and BREASTCANCER.ORG founder, in,open letter to Congress today about ,Breast Cancer ... ... H.R. 758, WASHINGTON, May 22 "Mandatory drive-through,mastectomies is ... complications," says Dr. Marisa Weiss, a,leading breast oncologist and Founder and ...
... of Rochester Reports SPY Accurately Detects Renal Tumors in the ... ... 22 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of real-time imaging ... results of a clinical study,of the SPY(R) Intra-operative Imaging System in urology ...
... With the ... Internet Users, PARIS, May 22 Publicis ... full-service digital marketing,agency, EmporioAsia. Effective immediately, the agency ... Vincent Kobler heading the renamed,agency. Operating alongside Arc ...
Cached Medicine News:Health News:Equine Partners in Counseling (EPIC) Training Is Changing the Face of Mental Health 2Health News:Craniomaxillofacial Plate & Screw Market To Grow to Almost $300 Million by 2012 2Health News:CME Publication Tackles a Problem that is a Real Headache for Women 2Health News:Drive-Through Mastectomies Threaten Patients' Lives 2Health News:Novadaq's SPY System was Topic of Best Poster in Scientific Session at AUA 2Health News:Novadaq's SPY System was Topic of Best Poster in Scientific Session at AUA 3Health News:Publicis Groupe Acquires EmporioAsia, Leading Digital Agency in China 2Health News:Publicis Groupe Acquires EmporioAsia, Leading Digital Agency in China 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: